MAP2K7 and gastric cancer: Treatment with MEK inhibitors also led to an increase in AKT activity, reducing the cellular sensitivity of breast and gastric cancer cells to these inhibitors (Hoeflich et al., 2009; Mirzoeva et al., 2009; Yoon et al., 2009).